GlassScriptPhysician profile
Robert Blair Werner
NPI 1487656633
$1,707.25
in general payments reported to CMS, 2019-2025
23 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $140 · 2021: $217 · 2022: $195 · 2023: $440 · 2024: $393 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.72 | 2022-2025 | Durysta, Alphagan P, Vuity |
| Sun Pharmaceutical Industries INC. | $241.45 | 2019-2025 | Cequa |
| Allergan, INC. | $139.19 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $110.68 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $91.57 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $90.80 | 2019-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $86.55 | 2022-2023 | Miebo, Vyzulta |
| Thea Pharma INC. | $79.08 | 2023-2024 | Iyuzeh |
| Harrow Eye, LLC | $71.81 | 2024-2025 | Vevye |
| Amgen INC. | $68.32 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $66.91 | 2022-2025 | Hydrus Microstent, Simbrinza |
| Astellas Pharma US INC | $56.23 | 2023 | |
| Kala Pharmaceuticals, INC. | $55.88 | 2021-2022 | |
| Ocular Therapeutix, INC. | $49.27 | 2023-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $38.63 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $38.48 | 2020-2021 | |
| Halozyme INC | $34.84 | 2024-2025 | Hylenex Recombinant |
| Mallinckrodt Hospital Products INC. | $24.21 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.45 | 2023 | Flarex |
| Rxsight INC | $16.50 | 2024 | Rxsight Injector Handpiece, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Oyster Point Pharma, INC. | $15.54 | 2022 | |
| Biotissue Holdings INC. | $15.05 | 2025 | |
| Coopervision INC. | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Werner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.